Geron Co. (GERN) Stake Lessened by Jane Street Group LLC

Jane Street Group LLC lowered its stake in shares of Geron Co. (NASDAQ:GERN) by 22.4% during the 4th quarter, HoldingsChannel reports. The fund owned 153,033 shares of the biopharmaceutical company’s stock after selling 44,092 shares during the quarter. Jane Street Group LLC’s holdings in Geron were worth $153,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. SVA Plumb Wealth Management LLC increased its holdings in shares of Geron by 98.8% during the fourth quarter. SVA Plumb Wealth Management LLC now owns 50,300 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 25,000 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Geron by 99.6% during the fourth quarter. SG Americas Securities LLC now owns 56,479 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 28,181 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Geron by 11.2% during the third quarter. Teachers Advisors LLC now owns 326,525 shares of the biopharmaceutical company’s stock valued at $575,000 after acquiring an additional 32,948 shares in the last quarter. IHT Wealth Management LLC acquired a new position in shares of Geron during the fourth quarter valued at about $37,000. Finally, MetLife Investment Advisors LLC increased its holdings in shares of Geron by 50.1% during the third quarter. MetLife Investment Advisors LLC now owns 117,168 shares of the biopharmaceutical company’s stock valued at $206,000 after acquiring an additional 39,095 shares in the last quarter. Hedge funds and other institutional investors own 33.54% of the company’s stock.

Several equities analysts have recently issued reports on the stock. Needham & Company LLC upgraded shares of Geron from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Tuesday, April 9th. BidaskClub downgraded shares of Geron from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. BTIG Research assumed coverage on shares of Geron in a report on Tuesday, February 12th. They set a “buy” rating and a $4.00 price objective on the stock. ValuEngine upgraded shares of Geron from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, B. Riley upgraded shares of Geron from a “neutral” rating to a “buy” rating and upped their price objective for the company from $1.50 to $3.25 in a report on Thursday, January 31st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Geron presently has a consensus rating of “Buy” and an average price target of $3.31.

In related news, EVP Melissa Kelly Behrs sold 120,635 shares of the company’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $2.00, for a total value of $241,270.00. The sale was disclosed in a document filed with the SEC, which is available at this link. 8.20% of the stock is owned by corporate insiders.

Shares of NASDAQ GERN opened at $1.77 on Friday. Geron Co. has a 52 week low of $0.95 and a 52 week high of $6.99.

Geron (NASDAQ:GERN) last issued its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.05). The firm had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.22 million. Geron had a negative return on equity of 17.61% and a negative net margin of 2,534.43%. On average, equities analysts anticipate that Geron Co. will post -0.34 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/geron-co-gern-stake-lessened-by-jane-street-group-llc.html.

About Geron

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

See Also: Quiet Period Expirations

Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERN).

Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.